Investigational drug · Phase 2
Emavusertib
Also called: CA-4948
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
11
Any phase or sponsor naming "Emavusertib"
First trial start
2017
Dec 28, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Emavusertib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed Hematologic Malignancy
- Refractory Hematologic Malignancy
- Relapsed Primary Central Nervous System Lymphoma
- Refractory Primary Central Nervous System Lymphoma
- Chronic Lymphocytic Leukemia
- B-cell Malignancies
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Emavusertib" as an intervention, largest first.
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
Curis, Inc.Industry
NCT04278768 · 366 participants (planned) · Start Jul 6, 2020 · Primary completion Apr 1, 2026
Drug: Emavusertib; Venetoclax and 1 more · For: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
Sites: Tampa, Florida; Atlanta, Georgia; Chicago, Illinois · 32 sites in all
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)Pivotal-lookingNot yet recruiting
National Cancer Institute (NCI)NIH
NCT07463820 · 270 participants (planned) · Start Dec 18, 2026 · Primary completion Dec 31, 2027
Drug: Emavusertib; Epoetin Alfa and 1 more · For: Myelodysplastic Syndrome
Curis, Inc.Industry
NCT03328078 · 152 participants (planned) · Start Dec 28, 2017 · Primary completion Jul 2027
Drug: Emavusertib; Ibrutinib · For: Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy; Relapsed Primary Central Nervous System Lymphoma and 1 more
Sites: Phoenix, Arizona; Duarte, California; Santa Monica, California · 45 sites in all
Curis, Inc.Industry
NCT07271667 · 108 participants (planned) · Start Apr 23, 2026 · Primary completion Nov 2027
Drug: Emavusertib; Zanubrutinib · For: Chronic Lymphocytic Leukemia; B-cell Malignancies
Sites: Miami Beach, Florida; Rochester, Minnesota; Florham Park, New Jersey · 11 sites in all
Washington University School of MedicineAcademic, hospital or other
NCT07107750 · 48 participants (planned) · Start Mar 27, 2026 · Primary completion Jun 30, 2030
Drug: Emavusertib; Gemcitabine and 2 more · For: Metastatic Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma
Sites: St Louis, Missouri
- CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic CancerSuspended
National Cancer Institute (NCI)NIH
NCT05685602 · 43 participants (planned) · Start Jun 12, 2023 · Primary completion Apr 30, 2027
Drug: Emavusertib; Gemcitabine Hydrochloride and 1 more · For: Metastatic Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 and 1 more
Sites: Duarte, California; Irvine, California; Orange, California · 26 sites in all
University of LeipzigAcademic, hospital or other
NCT05178342 · 38 participants · Start Jan 1, 2022 · Primary completion Jul 31, 2024
Drug: CA-4948 · For: Myelodysplastic Syndromes; Anemia
Sites: Berlin, Germany; Cottbus, Germany; Dresden, Germany · 15 sites in all
National Cancer Institute (NCI)NIH
NCT06439836 · 27 participants (planned) · Start May 5, 2025 · Primary completion Jun 1, 2027
Drug: Emavusertib; Pembrolizumab · For: Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma
Sites: Duarte, California; Irvine, California; La Jolla, California · 11 sites in all
National Cancer Institute (NCI)NIH
NCT06696768 · 24 participants (planned) · Start Jun 23, 2025 · Primary completion Dec 31, 2026
Drug: Bevacizumab; Emavusertib and 3 more · For: Metastatic Colorectal Adenocarcinoma; Stage III Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8 and 1 more
Sites: Gainesville, Florida; Shiloh, Illinois; Fairway, Kansas · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.
Platzbecker AS, Zoldan K, Brauer D, et al. · Commun Med (Lond) 2026
- Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib.
Von Roemeling CA, Doonan BP, Carpenter SL, et al. · Mol Cancer Ther 2026
- A heterobifunctional IRAK4-targeting degrader impairs myddosome signaling in acute kidney injury and ameliorates kidney fibrosis.
Lopez-Marfil M, Wang X, Lopez-Cantu DO, et al. · Commun Biol 2026
- Meeting Report From the 2024 Symposium on IRAK4 in Cancer: Highlights and Clinical Updates.
Winer ES, Konopleva M, Tun HW, et al. · Clin Lymphoma Myeloma Leuk 2025
- Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma.
Korah M, Reveron-Thornton RF, Fallah M, et al. · Cell Rep 2025
- Discovery of pyrrolo[2,3-d]pyrimidine derivatives as novel FLT3/IRAK4 inhibitors.
Yuan H, Gao Y, Wang P, et al. · Eur J Med Chem 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.